secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-095744
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q2 net loss $29.9M; expands ADI-001 into three more autoimmune indications
--------------------------------------------------------------------------------

- Net loss $29.9M ($0.33/share) vs $32.4M ($0.75) in Q2 2023; cash $224.1M, sufficient into H2 2026.
- FDA cleared IND for ADI-001 in SLE, SSc, AAV; Fast Track for LN; enrollment starts Q3 2024 with data H1 2025.
- FDA cleared IND for ADI-270 in RCC with Fast Track Designation; Phase 1 to start Q4 2024, data H1 2025.
- R&D expenses $25.9M, down from $28.4M; G&A $6.9M, up from $6.5M.
- MCL enrollment ongoing in ADI-001 Phase 1 GLEAN study; clinical update Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024095744/0000950170-24-095744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024095744/acet-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer